Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Paclitaxel 77pembrolizumab 65Bevacizumab 58Carboplatin 57Specimen Handling 49Magnetic Resonance Spectroscopy 40Cisplatin 35olaparib 31Gemcitabine 26liposomal doxorubicin 24Biopsy 22Taxes 18Cyclophosphamide 18Topotecan 17Nivolumab 17Immunoglobulin G 15Doxorubicin 15niraparib 14Letrozole 14Disulfides 14lenvatinib 13fludarabine 13atezolizumab 12Surveys and Questionnaires 12Radiotherapy 11Drug Therapy 11abemaciclib 10Platinum 10Docetaxel 10Brachytherapy 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
romiplostim × Gynecologic × 90 days × Clear all
NCT03937154 2026-04-07

Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

Amgen

Phase 3 Active not recruiting
145 enrolled
BreastGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡